|
Affiliation |
Faculty of Medicine School of Medicine Department of Developmental and Urological-Reproductive Medicine, Urology |
|
Title |
Assistant Professor |
|
Related SDGs |
|
TAKEI Akinori
|
|
|
Papers 【 display / non-display 】
-
前立腺癌に対する恥骨前立腺靭帯温存ロボット支援前立腺全摘除術の治療成績 Reviewed
武井亮憲
西日本泌尿器科学会誌 88 ( 3 ) 121 - 127 2026.2
Authorship：Lead author Publishing type：Research paper (scientific journal)
-
Abe J., Murashima T., Kojima S., Ueno T., Takei A., Nakai N., Akioka T., Kamoto T., Sawada A.
International Journal of Clinical Oncology 2026.2
Publishing type：Research paper (scientific journal) Publisher：International Journal of Clinical Oncology
Advances in immuno-oncology (IO)-based systemic therapies have improved treatment outcomes for patients with metastatic renal cell carcinoma (mRCC). However, long-term survival of these patients remains challenging, highlighting the need to reassess the role of local and metastasis-directed treatments. Cytoreductive nephrectomy (CN) has traditionally been a part of the therapeutic armamentarium for mRCC, and evidence from the targeted therapy era—most notably the CARMENA and SURTIME trials—indicates that deferred CN after initial systemic therapy may benefit carefully selected patients. In the IO era, prospective evidence regarding CN is lacking, although ongoing trials, such as NORDIC-SUN and PROBE, are expected to refine patient selection and optimal timing. Real-world analysis reveals a significant decline in conducting CN since 2018. However, CN remains associated with improved overall survival of patients who received several IO-based first-line regimens after adjustment for baseline characteristics. Metastasis-directed treatments, including metastasectomy and local interventions for bone metastases, continue to exhibit potential survival benefits and may maintain functional status when complete resection of lesions is achievable. Considering the absence of definitive prospective data applicable to routine clinical practice, individualized treatment strategies should consider CN and local therapies alongside systemic treatment response, tumor biology, and patient-specific prognostic factors.